167 related articles for article (PubMed ID: 27045535)
1. [Anticancer drugs: Which prices for therapeutic innovations?].
Gonçalves A; Maraninchi D; Marino P
Bull Cancer; 2016 Apr; 103(4):361-7. PubMed ID: 27045535
[TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
[TBL] [Abstract][Full Text] [Related]
4. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
[TBL] [Abstract][Full Text] [Related]
5. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
6. [Cancer medicines: reasons for anger].
Gonçalves A; Maraninchi D; Vernant JP
Rev Prat; 2017 Feb; 67(2):141-145. PubMed ID: 30512845
[TBL] [Abstract][Full Text] [Related]
7. Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.
Lemieux J; Audet S
Curr Oncol; 2018 Jun; 25(Suppl 1):S161-S170. PubMed ID: 29910659
[TBL] [Abstract][Full Text] [Related]
8. Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time.
Saluja R; Arciero VS; Cheng S; McDonald E; Wong WWL; Cheung MC; Chan KKW
J Oncol Pract; 2018 May; 14(5):e280-e294. PubMed ID: 29601250
[TBL] [Abstract][Full Text] [Related]
9. [Not Available].
Thierry JP
Bull Cancer; 2016 Nov; 103 Suppl 1():S186-S192. PubMed ID: 28057183
[TBL] [Abstract][Full Text] [Related]
10. [The French medecine pricing committee].
Giorgi D
Ann Pharm Fr; 2017 Sep; 75(5):373-384. PubMed ID: 28583317
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center.
Wilson L; Lin T; Wang L; Patel T; Tran D; Kim S; Dacey K; Yuen C; Kroon L; Brodowy B; Rodondi K
J Manag Care Spec Pharm; 2017 Feb; 23(2):163-169. PubMed ID: 28125363
[TBL] [Abstract][Full Text] [Related]
12. Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs.
Becker DJ; Lin D; Lee S; Levy BP; Makarov DV; Gold HT; Sherman S
J Oncol Pract; 2017 Jul; 13(7):e653-e665. PubMed ID: 28493760
[TBL] [Abstract][Full Text] [Related]
13. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.
Stahel R; Bogaerts J; Ciardiello F; de Ruysscher D; Dubsky P; Ducreux M; Finn S; Laurent-Puig P; Peters S; Piccart M; Smit E; Sotiriou C; Tejpar S; Van Cutsem E; Tabernero J
Cancer Treat Rev; 2015 Feb; 41(2):129-35. PubMed ID: 25533737
[TBL] [Abstract][Full Text] [Related]
14. Drug pricing and value in oncology.
Danzon PM; Taylor E
Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
[TBL] [Abstract][Full Text] [Related]
15. From Bench to Bedside: Targeted Therapy, Denosumab, and 21st Century Orthopaedics: Targets Abound, But Where Are The Therapies?
Potter BK
Clin Orthop Relat Res; 2016 Apr; 474(4):892-4. PubMed ID: 26872915
[No Abstract] [Full Text] [Related]
16. [Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital].
Baudouin A; Fargier E; Cerruti A; Dubromel A; Vantard N; Ranchon F; Schwiertz V; Salles G; Souquet PJ; Thomas L; Bérard F; Nancey S; Freyer G; Trillet-Lenoir V; Rioufol C
Bull Cancer; 2017 Jun; 104(6):538-551. PubMed ID: 28237353
[TBL] [Abstract][Full Text] [Related]
17. The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017.
Rodwin MA; Mancini J; Duran S; Jalbert AC; Viens P; Maraninchi D; Gonçalves A; Marino P
Eur J Cancer; 2021 Mar; 145():11-18. PubMed ID: 33412466
[TBL] [Abstract][Full Text] [Related]
18. [Health care expenditures linked to the use of targeted therapies and diagnostic tests for cancer patients].
Marino P; Bertucci F; Gonçalves A; Seror V
Med Sci (Paris); 2012 Mar; 28 Spec No 1():19-23. PubMed ID: 22494652
[TBL] [Abstract][Full Text] [Related]
19. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.
Vivot A; Jacot J; Zeitoun JD; Ravaud P; Crequit P; Porcher R
Ann Oncol; 2017 May; 28(5):1111-1116. PubMed ID: 28453694
[TBL] [Abstract][Full Text] [Related]
20. Era of personalized medicine may herald end of soaring cancer costs.
Keogh B
J Natl Cancer Inst; 2012 Jan; 104(1):12-3, 16-7. PubMed ID: 22173586
[No Abstract] [Full Text] [Related]
[Next] [New Search]